Abstract 43P
Background
Breast cancer remains a significant concern worldwide. Risk-based screening, which tailors screening recommendations to individual risk levels, has been shown to enhance patient stratification. However, most research on model development focuses on Western populations, leaving the predictive accuracy of these models for Southeast Asian populations largely uncharacterized.
Methods
We conducted an observational case-control study comprising 305 Indonesian women to assess the applicability of published risk models to the local population. We employed a combined risk model to classify patients as either elevated or average risk. Our combined model evaluates two separate risk factors: genetic risk, assessed using ancestry-adjusted PRS scores based on the Mavaddat model, and clinical risk, evaluated using the Gail model. The performance of each individual model and their combined effectiveness were analyzed using the Area Under the Curve (AUC) and Odds Ratio (OR).
Results
Individual risk models retained their predictive efficacy in the Indonesian context. Specifically, the AUC achieved for genetic risk is AUC of 0.674 (p = 1.28 x 10-3; Risk group: OR = 3.16; p = 2.5 x 10-1). For clinical risk, the AUC stands at 0.674 (p = 5.16 x 10-4; Risk group: OR = 7.636; p = 6.1 x 10-3). Remarkably, when combined, the AUC increased to 0.701 (Risk group: OR= 3.897; p = 4.28 x 10-2), signifying the benefits of a multi-factor model. Based on a subset of the samples taken from this study, the Nala Breast Cancer Risk genetic risk algorithm generated higher AUC when compared to a leading third-party software that uses the same PRS model for breast cancer (0.63 vs 0.55). This improvement is primarily due to our method of translating PRS scores into categorical outcomes, which integrates localized disease incidence and mortality rates.
Conclusions
Our findings demonstrate for the first time the applicability of the Polygenic Risk Score using Mavaddat model and clinical score using Gail model to Indonesian populations. In addition, our study shows that, within this demographic, combined risk models provide a superior predictive framework compared to single-factor approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NalaGenetics.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract